Antiviral therapy for patients with chronic hepatitis C

Seminars in Liver Disease

Volumn 20, Issue 2, 2000, Pages 185-199

  Heathcote, J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Chronic hepatitis C; Combination therapies; Interferon; Monotherapy

Indexed keywords

CONSENSUS INTERFERON; REBETRON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ANTIVIRAL ACTIVITY; ARTICLE; BLOOD TOXICITY; CARDIOTOXICITY; CHRONIC HEPATITIS; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; HEPATITIS C; HUMAN; INCIDENCE; KIDNEY FAILURE; META ANALYSIS; PRIORITY JOURNAL; TERATOGENICITY;

EID: 0033868989     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-9941     Document Type: Article

References (96)

1. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients
2. Side effects of alpha interferon
3. The clinical pharmacology of ribavirin
4. Interferon alfa 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
5. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
6. Is an 'a la carte' combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?
7. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy
8. Long-term course of interferon-treated chronic hepatitis C
9. 10-year follow-up after Interferon-α therapy for chronic hepatitis C
10. Prognosis of chronic hepatitis C: Results of a large, prospective cohort study
11. Durability of serological remission in chronic hepatitis C treated with Interferon alpha-2b
12. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon
13. Durability of viral response to interferon alone or in combination with oral ribavirin in patients with chronic hepatitis C [Abstract 570]
14. Effect of Interferon therapy on hepatitis C virus RNA in whole blood, plasma and peripheral mononuclear cells
15. Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis
16. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis
17. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C
18. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C
19. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C
20. Interferon therapy lance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan
21. A randomized controlled trial of maintenance Interferon therapy for patients with chronic hepatitis C virus and persistent viremia
22. Long-term mortality after transfusion-associated non-a, non-b hepatitis
23. Pevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening
24. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin
25. 45 year follow-up of hepatitis C virus infection in healthy young adults
26. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: A prospective observation of 2215 patients
27. The long-term pathological evolution of chronic hepatitis C
28. Natural history of liver fibrosis progression in patients with chronic hepatitis C
29. Histological progression during short-term follow-up of patients with chronic hepatitis C virus infection
30. Prognosis of chronic hepatitis C: Results of a large, prospective cohort study
31. Outpatient liver biopsy: How safe is it?
32. Complications following percutaneous liver biopsy: A multicentre retrospective study on 68,276 biopsies
33. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view
34. Reduction of health-related quality of life in chronic hepatitis C and improvement with Interferon therapy
35. Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response
36. Fatigue does not correlate with the degree of hepatitis or the presence of autoimmune disorders in chronic hepatitis C infection
37. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity
38. Recombinant Interferon-α for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus
39. Treatment with recombinant α-interferon of chronic hepatitis C in anti-HIV positive patients
40. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus
41. Hepatitis C viral infection in the immunosuppressed patient
42. Ribavirin antagonizes the effect of azidothymidine on HIV replication
43. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C
44. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients
45. Interferon and ribavirin treatment in patients with hemophilia or von Willebrand disease infected with hepatitis C: An update [Abstract 430]
46. A double-blind controlled trial of recombinant interferon-α2b in hemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels
47. Impact of hepatitis B and C on kidney transplantation outcome
48. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients
49. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus
50. Interferon for mixed cryoglobulinemia associated with hepatitis C
51. Low-dose Interferon-α for mixed cryoglobulinemia associated with hepatitis c virus
52. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to α-Interferon therapy
53. Effect of alpha-Interferon on hepatitis C virus chronic infection in mixed cryoglobulinemia patients
54. Patients with splenic lymphoma with villous lymphocytes associated with hepatitis C infection may enter in complete clinical response after reduction of viral load
55. Interferon-α treatment of hepatitis C virus-associated mixed cryoglobulinemia
56. Response to high-dose Interferon-α after failure of standard therapy in MPGN associated with hepatitis c virus infection
57. Response to interferon α treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus
58. Interferon-α therapy for hepatitis C virus infection after liver transplantation
59. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation
60. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation
61. Predictors of patient and graft survival following liver transplantation for hepatitis C
62. Racial differences in responses to therapy with interferon in chronic hepatitis C
63. The impact of race on response to anti-viral therapy in patients with chronic hepatitis C [Abstract 568]
64. Efficacy of Interferon treatment for patients with chronic hepatitis C: Comparison of response in cirrhotics, fibrotics or nonfibrotics
65. Treatment of hepatitis C virus-related cirrhosis: A randomized controlled trial of Interferon alfa-2b versus no treatment
66. Prospective study of Interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA
67. Multinational evaluation of the efficacy and safety of once-weekly peginterferon alfa 2a (PEG-IFN) in patients with chronic hepatitis C (CHC) with compensated cirrhosis [Abstract 621]
68. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C
69. Human leukocyte antigen class IX alleles may affect response of chronic hepatitis C to interferon therapy
70. Genotype, viral load and age as independent predictors of treatment outcome of interferon-α2a treatment in patients with chronic hepatitis C
71. Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial
72. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: Results of an international randomized controlled trial
73. Randomised doubleblind, placebo-controlled trial of interferon alfa 2b with and without ribavirin for chronic hepatitis C
74. Combination therapy with peginterferon alfa-2a (PEG-IFN) and ribavirin in the treatment of patients with chronic hepatitis C (CHC): A phase II open-label study [Abstract 145]
75. Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C
76. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon alfa therapy
77. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa
78. Predicting response to initial therapy with interferon alpha and ribavirin in chronic hepatitis C using serum HCV RNA during therapy [Abstract 818]
79. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT
80. Early prediction and mechanism of the ribavirin/IFN alpha dual therapy effect on chronic hepatitis C virus (HCV) infection [Abstract 595]
81. Interferon alfa 2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
82. Re-treatment of chronic hepatitis C with consensus Interferon
83. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with inteferon-alpha2a
84. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials
85. Interferon alpha-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: A randomized trial
86. Evolution of viral quasispecies in interferon treated patients with chronic hepatitis C infection
87. Response to higher doses of Interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial
88. Breakthrough during recombinant Interferon alfa therapy in patients with chronic hepatitis C virus infection: Prevalence, etiology and management
89. Chronic hepatitis C virus patients with breakthroughs during Interferon treatment can successfully be retreated with Consensus Interferon
90. Relationship between biochemical, virological, and histological response during Interferon treatment of chronic hepatitis C
91. Use of high-dose interferon in the treatment of chronic hepatitis C
92. Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha Interferon
93. Interferon and Ursodeoxycholic Acid combined therapy in the treatment of chronic viral C hepatitis: Results from controlled randomized trial in 80 patients
94. Interferon plus thymosin α-1 treatment of chronic hepatitis C infection: A meta analysis